Evidence map›Paper›PMID 38542305›Full record

ArticleInternational journal of molecular sciences2024

Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists.

Najam A Sharif, J Cameron Millar, Gulab Zode, Takashi Ota

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Triptolide clearsFrontiers in pharmacology · 2026
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

Najam A SharifOphthalmology Innovation Center, Santen Inc., Emeryville, CA 94608, USA.
J Cameron MillarDepartment of Pharmacology & Neuroscience, North Texas Eye Research Institute (NTERI), University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Gulab ZodeDepartment of Ophthalmology and Center for Translational Vision Research, University of California, Irvine, CA 92617, USA.
Takashi OtaOphthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Nara 630-0101, Japan.ORCID 0000-0003-2366-2819
Creighton University · USSanten (Japan) · JPUniversity of California, Irvine · USUniversity of North Texas · US

Funding

Crosstalk Between Unfolded Protein Response and Autophagy for the Treatment of GlaucomaR01EY026177 · NEI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI ZODE, GULAB · 2016 to 2025
$3.8M
Impaired TRVP4-eNOS signaling in TM contributes to glaucomaR01EY034238 · NEI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI Swapnil K. Sonkusare, Gulab Zode · 2022 to 2026
$2.2M
NEI NIH HHS EY026177NEI NIH HHS R01 EY026177NEI NIH HHS R01 EY034238
6 · The paper itself

Abstract

We tested five chemically and metabolically stable prostaglandin (PG) receptor agonists in a mouse model of dexamethasone-induced ocular hypertension (OHT). Whilst all compounds significantly (

Indexed as

AcetamidesAcetatesMisoprostolOcular HypertensionPyrazinesSulfonamidesAnimalsMiceReceptors, ProstaglandinReceptors, Prostaglandin E, EP4 SubtypeSteroidsTissue Plasminogen ActivatorAcetamidesAcetatesMisoprostolPF 04217329PyrazinesReceptors, ProstaglandinReceptors, Prostaglandin E, EP4 SubtypeselexipagSteroidsSulfonamidesTissue Plasminogen ActivatorButaprostEP2 receptor agonistIOPocular hypertensionPF-04217329steroid

Identifiers

PMID38542305
PMCPMC10970031
OpenAlexW4392864701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.